These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 9769948)

  • 1. [Germline mutations of the p53 gene].
    Frebourg T
    Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Li-Fraumeni syndrome].
    Frebourg T
    Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
    Gonzalez KD; Noltner KA; Buzin CH; Gu D; Wen-Fong CY; Nguyen VQ; Han JH; Lowstuter K; Longmate J; Sommer SS; Weitzel JN
    J Clin Oncol; 2009 Mar; 27(8):1250-6. PubMed ID: 19204208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Li-Fraumeni syndrome: update, new data and guidelines for clinical management].
    Frebourg T; Abel A; Bonaiti-Pellie C; Brugières L; Berthet P; Bressac-de Paillerets B; Chevrier A; Chompret A; Cohen-Haguenauer O; Delattre O; Feingold J; Feunteun J; Frappaz D; Fricker JP; Gesta P; Jonveaux P; Kalifa C; Lasset C; Leheup B; Limacher JM; Longy M; Nogues C; Oppenheim D; Sommelet D; Soubrier F; Stoll C; Stoppa-Lyonnet D; Tristant H
    Bull Cancer; 2001 Jun; 88(6):581-7. PubMed ID: 11459705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
    Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
    Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germ-line splicing mutation of the p53 gene in a cancer-prone family.
    Warneford SG; Witton LJ; Townsend ML; Rowe PB; Reddel RR; Dalla-Pozza L; Symonds G
    Cell Growth Differ; 1992 Nov; 3(11):839-46. PubMed ID: 1467311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
    Birch JM; Hartley AL; Tricker KJ; Prosser J; Condie A; Kelsey AM; Harris M; Jones PH; Binchy A; Crowther D
    Cancer Res; 1994 Mar; 54(5):1298-304. PubMed ID: 8118819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [When is it useful to look for TP53 germline gene mutations in families of oncology patients?].
    Trková M; Sedlácek Z
    Cas Lek Cesk; 2003; 142(4):220-5. PubMed ID: 12841124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
    Evans SC; Lozano G
    Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
    Bougeard G; Sesboüé R; Baert-Desurmont S; Vasseur S; Martin C; Tinat J; Brugières L; Chompret A; de Paillerets BB; Stoppa-Lyonnet D; Bonaïti-Pellié C; Frébourg T;
    J Med Genet; 2008 Aug; 45(8):535-8. PubMed ID: 18511570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative frequency and morphology of cancers in carriers of germline TP53 mutations.
    Birch JM; Alston RD; McNally RJ; Evans DG; Kelsey AM; Harris M; Eden OB; Varley JM
    Oncogene; 2001 Aug; 20(34):4621-8. PubMed ID: 11498785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.
    Malkin D; Jolly KW; Barbier N; Look AT; Friend SH; Gebhardt MC; Andersen TI; Børresen AL; Li FP; Garber J
    N Engl J Med; 1992 May; 326(20):1309-15. PubMed ID: 1565144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Li-Fraumeni syndrome and germ-line mutations of the p53 gene].
    Leblanc T; Soussi T
    Arch Pediatr; 1994 Jan; 1(1):61-70. PubMed ID: 8087224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.
    Quesnel S; Verselis S; Portwine C; Garber J; White M; Feunteun J; Malkin D; Li FP
    Oncogene; 1999 Jul; 18(27):3970-8. PubMed ID: 10435620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies.
    Pötzsch C; Voigtländer T; Lübbert M
    J Cancer Res Clin Oncol; 2002 Aug; 128(8):456-60. PubMed ID: 12200603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.